Bertin Pharma is acquired by Bertin Technologies on January 2018. The Bioreagent activity is now included into the Business Unit Systems & Instrumentation.

Bertin Technologies decided to focus on the strategic product ranges of Bioreagents & Bioanalytic Tools. This activity will reinforce the offer of the company in the Life Sciences market, already known as a key player for sample preparation (with the Precellys tissue homogenizers) and for cell imaging (with the new InCellis, digital cell imager).

These synergies provide to Bertin Technologies a higher added value at the crossroad of reagents and equipment.
All your contacts from the Bioreagent activity remain the same, and will be pleased to tell you more about this new organization.